Login to Your Account



Biotech Battles Blindness: Two Unique Breakthroughs

Early Success Reported in hESC Trial for Macular Degeneration

By Nuala Moran
BioWorld Today Correspondent

Tuesday, January 24, 2012

LONDON – The first patient in the first human embryonic stem cell (hESC) trial to be held in Europe left Moorfields Eye Hospital in London on Monday after being treated for macular degeneration. At the same time, Advanced Cell Technology (ACT) Inc., the company behind the trial of the hESC-derived retinal pigment epithelium cells published initial clinical data on the U.S. arm of the study, showing tantalizing early signs of efficacy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription